An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis ; volume:10 ; number:1-2 ; year:2019 ; pages:98-114
Molecular syndromology ; 10, Heft 1-2 (2019), 98-114
- Creator
-
Seda, Marian
Geerlings, Maartje
Lim, Peggy
Jeyabalan-Srikaran, Jeshmi
Cichon, Ann-Christin
Scambler, Peter J.
Beales, Philip L.
Hernandez-Hernandez, Victor
Stoker, Andrew W.
Jenkins, Dagan
- DOI
-
10.1159/000491567
- URN
-
urn:nbn:de:101:1-2019030623143242142831
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Seda, Marian
- Geerlings, Maartje
- Lim, Peggy
- Jeyabalan-Srikaran, Jeshmi
- Cichon, Ann-Christin
- Scambler, Peter J.
- Beales, Philip L.
- Hernandez-Hernandez, Victor
- Stoker, Andrew W.
- Jenkins, Dagan
Other Objects (12)
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Biobank for craniosynostosis and faciocraniosynostosis, rare pediatric congenital craniofacial disorders: a study protocol
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Craniofacial morphology and growth in Muenke syndrome, Saethre-Chotzen syndrome, and TCF12-related craniosynostosis
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Biobank for craniosynostosis and faciocraniosynostosis, rare pediatric congenital craniofacial disorders: a study protocol
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Craniofacial morphology and growth in Muenke syndrome, Saethre-Chotzen syndrome, and TCF12-related craniosynostosis
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Biobank for craniosynostosis and faciocraniosynostosis, rare pediatric congenital craniofacial disorders: a study protocol
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor